PREVENTION OF NON-SPECIFIC AIRWAY HYPERREACTIVITY AFTER ALLERGEN CHALLENGE IN GUINEA-PIGS BY THE PAF RECEPTOR ANTAGONIST SDZ 64-412

被引:45
作者
HAVILL, AM [1 ]
VANVALEN, RG [1 ]
HANDLEY, DA [1 ]
机构
[1] SANDOZ INC,RES INST,E HANOVER,NJ 07936
关键词
D O I
10.1111/j.1476-5381.1990.tb14715.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1. Allergen challenge by aerosol in sensitized guinea-pigs elicited non-specific airway hyperreactivity assessed by reactivity to i.v. histamine or acetylcholine. Airway hypereactivity to histamine persisted for at least 48 h and was accompanied by pulmonary eosinophilia as determined by bronchoalveolar lavage cell analysis. 2. Airway hyperreactivity was independent of vagal reflex mechanisms since it was not abrogated by bilateral vagotomy. 3. The novel platelet-activating factor (PAF) receptor antagonist SDZ 64-412 inhibited the development of airway hyperreactivity, as measured 24 h after aerosol allergen challenge, when given as a single treatment orally 2 h before allergen challenge. The PAF receptor antagonist WEB 2086 as well as methylprednisolone and ketotifen also showed efficacy in preventing development of airway hyperreactivity. 4. Neither the two PAF antagonists nor ketotifen had any effect on bronchoalveolar lavage (BAL) eosinophil numbers. Methylprednisolone was the only substance which readily prevented eosinophil recruitment in addition to airway hyperreactivity. 5. We conclude that allergen-induced airway hyperreactivity in guinea-pigs is inhibited by prophylactic anti-asthma drugs and specific PAF receptor antagonists, thus demonstrating a pivotal role of PAF in this response. There was a lack of correlation between airway hyperreactivity and the presence of BAL eosinophils.
引用
收藏
页码:396 / 400
页数:5
相关论文
共 32 条
[1]  
ANDERSSON P, 1981, BRIT J PHARMACOL, V74, P604
[2]  
BARNES PJ, 1986, AM REV RESPIR DIS, V134, P1289
[3]   PAF CLOSELY MIMICS PATHOLOGY OF ASTHMA [J].
BARNES, PJ ;
CHUNG, KF .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1987, 8 (08) :285-287
[4]  
CASALS-STENZEL J, 1986, Naunyn-Schmiedeberg's Archives of Pharmacology, V334, pR44
[5]   EFFECTS OF WEB-2086, A NOVEL ANTAGONIST OF PLATELET-ACTIVATING-FACTOR, IN ACTIVE AND PASSIVE ANAPHYLAXIS [J].
CASALSSTENZEL, J .
IMMUNOPHARMACOLOGY, 1987, 13 (02) :117-124
[6]  
CASALSSTENZEL J, 1987, J PHARMACOL EXP THER, V241, P974
[7]   A STUDY WITH BN-52021 DEMONSTRATES THE INVOLVEMENT OF PAF-ACETHER IN IGE-DEPENDENT ANAPHYLACTIC BRONCHOCONSTRICTION [J].
CIRINO, M ;
LAGENTE, V ;
LEFORT, J ;
VARGAFTIG, BB .
PROSTAGLANDINS, 1986, 32 (01) :121-126
[9]   THE EFFECT OF THE SELECTIVE PAF ANTAGONIST BN 52021 ON PAF-INDUCED AND ANTIGEN-INDUCED BRONCHIAL HYPER-REACTIVITY AND EOSINOPHIL ACCUMULATION [J].
COYLE, AJ ;
URWIN, SC ;
PAGE, CP ;
TOUVAY, C ;
VILLAIN, B ;
BRAQUET, P .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1988, 148 (01) :51-58
[10]   LG-30435, A NEW BRONCHODILATOR ANTIALLERGIC AGENT, INHIBITS PAF-ACETHER INDUCED PLATELET-AGGREGATION AND BRONCHOCONSTRICTION [J].
CRISCUOLI, M ;
SUBISSI, A ;
DAFFONCHIO, L ;
OMINI, C .
AGENTS AND ACTIONS, 1986, 19 (3-4) :246-250